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Abstract
Background: PH domains represent one of the most common domains in the human proteome. These domains
are recognized as important mediators of protein-phosphoinositide and protein-protein interactions.
Phosphoinositides are lipid components of the membrane that function as signaling molecules by targeting
proteins to their sites of action. Phosphoinositide based signaling pathways govern a diverse range of important
cellular processes including membrane remodeling, differentiation, proliferation and survival. Myo-Inositol
phosphates are soluble signaling molecules that are structurally similar to the head groups of phosphoinositides.
These molecules have been proposed to function, at least in part, by regulating PH domain-phosphoinositide
interactions. Given the structural similarity of inositol phosphates we were interested in examining the specificity of
PH domains towards the family of myo-inositol pentakisphosphate isomers.
Results: In work reported here we demonstrate that the C-terminal PH domain of pleckstrin possesses the
specificity required to discriminate between different myo-inositol pentakisphosphate isomers. The structural basis
for this specificity was determined using high-resolution crystal structures. Moreover, we show that while the PH
domain of Grp1 does not possess this high degree of specificity, the PH domain of protein kinase B does.
Conclusions: These results demonstrate that some PH domains possess enough specificity to discriminate
between myo-inositol pentakisphosphate isomers allowing for these molecules to differentially regulate interactions
with phosphoinositides. Furthermore, this work contributes to the growing body of evidence supporting myo-
inositol phosphates as regulators of important PH domain-phosphoinositide interactions. Finally, in addition to
expanding our knowledge of cellular signaling, these results provide a basis for developing tools to probe
biological pathways.
Background
PH (pleckstrin homology) domains represent one of the
most widely distributed domains in the human pro-
teome, being found in over 250 human proteins [1]
involved in a wide range of diverse biological function
(reviewed in [2]). Despite limited sequence similarity,
PH domains maintain a highly conserved architecture
(Figure 1, panel A) consisting of a seven-stranded anti-
parallel b sandwich closed at one end by a C-terminal a
helix. The opposing end remains open and accommo-
dates several variable loops. Loop b1/b2, located
between the first and second b strands often contains
positively charged residues involved in ligand binding.
In some PH domains this binding pocket region is
extended, adopting additional secondary structure ele-
ments (Figure 1, panel B). Ligand specificity is therefore
determined primarily by the overall structure and com-
position of the binding pocket region [3,4].
Soon after their discovery, PH domains were shown to
be important for targeting host proteins to specific sites at
the membrane via specific interactions with various phos-
phoinositides [5,6]. Phosphoinositides are lipid compo-
nents of the membrane that act as key signaling molecules
[7]. These lipids contain an inositol head group that can
be reversibly phosphorylated at the 3, 4 and 5 positions to
yield seven different phosphoinositides (Figure 1, panel D).
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any medium, provided the original work is properly cited.Phosphoinositides propagate cellular signals by recruiting
specific signaling proteins to the membrane by means of
phosphorylated inositol head groups. In addition to com-
prising the head groups of phosphoinositides, soluble myo-
inositol phosphates (IPs) themselves also function as
important second messengers [8,9]. In contrast to phos-
phoinositides, myo-inositol phosphates are reversibly phos-
phorylated at any or all of the six positions about the
inositol ring, giving rise to a large variety of different sig-
naling molecules. Phosphate groups attached to the inosi-
tol ring adopt equatorial positions at 5 of the 6 possible
locations. The remaining position is axial. This distribu-
tion of 5 equitorial and 1 axial positions is a key feature
of myo-inositol phosphates. Depending on the degree
of phosphorylation and the position of the phosphates,
the inositol ring itself adopts different conformations
further adding to the stereospecific diversity of this class
of signaling molecules.
myo-Inositol phosphates such as IP3 have been very well
characterized and shown to act as second messengers by
directly binding target proteins and modulating activity
[10-12]. In principle, the very abundant IP varieties could
also act as signaling molecules by directly regulating inter-
actions of PH domains with their phosphoinositide ligands
[10,13,14]. This is a particularly attractive hypothesis given
the structural diversity of inositol phosphates. Diversity in
inositol phosphate structure could result in interactions
with PH domains that vary in terms of both mode of bind-
ing and affinity. If so, IPs would provide cells with a
mechanism for fine tuning the many important PH
domain-phosphoinositide signaling interactions. Experi-
mental evidence in support of myo-inositol phosphates
Figure 1 PH domains and their ligands. Schematic representation of a typical PH domain is shown in panel A (Akt PH domain, residues 111-
115 omitted, PDB code 1UNQ). The core b sandwich is colored in blue, C-terminal a helix in green, loops in light pink and the b1/b2 loop in
orange. In panel B the PH domains from Grp1 (PDB code: 1FGY) and Akt (PDB code: 1UNQ) are aligned to highlight a unique structural feature
(colored in red) of the Grp1 PH domain (shown in grey). The variable b1/b2 loops of CPH (PDB code: 1ZM0) and Akt (PDB code: 1UNQ) are
illustrated in panel C and colored yellow and blue respectively. Black arrows highlight key differences in binding pockets. Panel D illustrates the
differences between phosphoinositides and inositol phosphates. Phosphate groups are shown as red dots.
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growing rapidly. IP3 was shown to efficiently dissociate the
phospholipase C (PLC) PH domain/PtdIns(4,5)P2 interac-
tion releasing PLC from the membrane when added exo-
genously or generated in cells [13,15]. Perhaps the most
notable example however, of an myo-inositol phosphate
regulating PH domain binding is that of the protein kinase
B (Akt) signaling pathway. Here, IP5(2), (nomenclature for
myo-inositol pentaphosphates adopted here is as follows;
IP5(#), myo-inositol pentaphosphate, number in brackets
indicates position missing a phosphate) one of the most
abundant inositol phosphates in most cell, was shown to
compete with PtdIns(3,4,5)P3 for binding to the PH
domain of Akt (PHAkt) thereby preventing its membrane
localization and subsequent activation [14].
Pleckstrin’s carboxyl terminal PH domain (CPH) is
known to bind PtdIns(3,4)P2 [16]. In a previous report,
we showed that the myo-inositol pentaphosphate (IP5),
IP5(4), is a particularly effective inhibitor of CPH binding
to PtdIns(3,4)P2 [17]. Given the central role of PH
domains in cell signaling and the large diversity of IPs,
we were interested in further analyzing the specificity of
binding for all IP5 isomers to several different PH
domains. The present study examines whether CPH is
capable of specifically recognizing different IP5 isomers.
Using high resolution crystal structures the structural
basis for observed IP5 specificity is further examined.
Finally, we extend the study to include 2 additional PH
domains from Grp1 and Akt. This work demonstrates
that CPH possesses the specificity required to differenti-
ate between different IP5 isomers. This high degree of
specificity was also found to be a property of the PHAkt
but not the Grp1 PH domain (PHGrp1). Together, results
presented here support a role for myo-inositol pentaki-
sphosphates as regulators of PH domain/phosphoinosi-
tide signaling and further demonstrate their potential
use as potent inhibitors of cell signaling.
Results and Discussion
Inhibition of CPH/PtdIns(3,4)P2 binding by inositol
pentakisphosphates
A previous study suggested that the inositol pentakispho-
sphate, IP5(4), is a particularly effective inhibitor of CPH
binding to PtdIns(3,4)P2 [17]. Since there are six different
IP5’s we sought to determine whether individual IP5 isomers
differed in their ability to inhibit CPH/phosphoinositide
interactions. This is an interesting question since IP5 iso-
mers are structurally quite similar, varying only in the posi-
tion of the 5 phosphate groups about their 6-carbon ring. A
difference in inhibitory properties would suggest that CPH
possesses a high degree of binding specificity enabling it to
discriminate between very subtle differences in ligands. The
ability of IP5’s to disrupt CPH/phosphoinositide interactions
was determined using SPR. In this assay, liposomes
containing PtdIns(3,4)P2 were immobilized to the sensor
surface and CPH binding determined in the presence and
absence of each IP5 isomer. As shown in Figure 2, the
family of IP5 isomers does in fact differ in their inhibitory
properties (P value < 0.0001). IP5(4) was a significantly better
binder relative to other IP5 molecules. The remaining IP5
isomers (IP5(1),I P 5(2),I P 5(3),I P 5(5) and IP5(6)) all had similar
affinities for CPH. The weakest inhibitor of CPH binding
was IP5(3). These observed differences in affinity indicate
that the binding pocket region of CPH is able to differenti-
ate between various arrangements of phosphate groups in
the IP5 family. The arrangement of phosphates displayed by
IP5(4) permits a particularly effective mode for interaction
with CPH (76% inhibition), presumably by accommodating
a favorable interaction not possible for other IP5 isomers. In
a previous study our group determined the crystal structure
of CPH bound to IP5(4). To elucidate the structural basis for
the observed specificity we determined the crystal structure
of CPH bound to one of the lower affinity isomers (IP5(6))
thereby allowing for a detailed structural comparison.
Structure of CPH/IP5(6) complex
The crystal structure of CPH bound to IP5(6) was deter-
mined to 1.7 Å and solved by molecular replacement using
the apo-CPH structure (PDB code 1ZM0) as a search
model. Data collection and model refinement statistics are
shown in Table 1. The final model, refined to R and Rfree
values of 0.18 and 0.24, was well ordered with the exception
of the b5/b6 loop (residues 301-310). This loop was simi-
larly disordered in previous structures of CPH suggesting it
is inherently flexible and most likely not directly involved in
ligand binding [17,18]. Three monomers of CPH were pre-
sent in the asymmetric unit. Each of these monomers was
highly similar to the others, having shared r.m.s deviations
of less than 0.2 Å. This similarity extended to the bound
IP5 molecules which were all refined with full occupancy in
the final model. The presence of IP5 resulted in only minor
Figure 2 Inhibition of CPH binding. Inhibition of CPH (50 µM)
binding to liposomes containing PtdIns(3,4)P2 by myo-inositol
pentakisphosphates (100 µM). Percent inhibition is plotted on the
y-axis for the different IP5 isomers. Percent inhibition values are
shown above the bars. Error bars represent +/- standard error of
mean (SEM).
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R257B’; IP5C-R257A) and its mode of binding to the CPH
domain is therefore not expected to be influenced signifi-
cantly by these crystal contacts. Comparison of the CPH/
IP5(6) structure with the CPH/IP5(4) structure revealed no
significant conformational changes in the overall structure
with one exception being the b3/b4 loop which adopted
variable conformations as shown in Figure 3.
A closer examination of the ligand binding region for
the CPH/IP5(4) and CPH/IP5(6) structures revealed sev-
eral important differences. While both IP5(4) and IP5(6)
bind in the same region, each isomer adopts very differ-
ent orientations in the b1/b2 binding pocket (Figure 4).
The inositol rings of both ligands are orientated with
the phosphate groups at the 5 position orientated simi-
larly relative to the plane of the b1/b2l o o p( F i g u r e4 ) .
The orientation of the two IP5 inositol rings differs by a
rotation of approximately 90° about the 5 position. This
large rotation results in IP5(6) making fewer interactions
and burying less surface area (387.3 Å
2 compared to
431.6 Å
2) in the binding pocket. These changes provide
clear structural evidence for the observed lower binding
affinity of IP5(6) compared to IP5(4). Interactions formed
between the two IP5 ligands and CPH are summarized
in Table 2. A detailed interaction list can be found in
Additional file 1, Table S1. These results demonstrate
that a single PH domain can utilize very different modes
of interaction and this difference may account for varia-
tions in the overall binding of IP isomers. This implies
that each IP5 could have a special role in differentially
regulating PH domain/phosphoinositide signaling.
Inhibition of PHGrp1 and PHAkt binding to PtdIns(3,4)P2 by
IP5 isomers
Having shown that CPH possesses a high degree of spe-
cificity we next asked whether this property is common
to other PH domains. The inhibitory properties of the
IP5 family were tested against two additional PH
domains from Grp1 and Akt. These PH domains have
been well characterized structurally making them ideal
for comparisons with CPH. The PH domain from Akt is
of particular interest since it was recently shown to be
regulated by IP5(2) interactions [14,19]. The study
Table 1 Crystallographic and data refinement statistics
CPH/IP5(6)
Date Collection
Space group C2
Unit-cell parameters (Å) a = 82.5, b = 47.6 and
c = 87.6 a = b = g =9 0
No. of molecules in asymmetric unit 3
Resolution range (Å)
a 50.00 - 1.65 (1.71-1.65)
Unique reflections 39 679
Data Redundancy
a 3.5 (2.5)
Completeness (%)
a 98.47 (91.4)
I/s(I)
a 26.6 (2.4)
Rmerge (%)
a 3.9 (36.3)
Model and refinement
Resolution range (Å)
a 87.71-1.75 (1.79-1.75)
Rwork (%) 18.0
Rfree (%) 24.3
No. of reflections 31 402 (28 793 in working
set and 2609 in test set)
No. of waters 315
r.m.s.d bond lengths (Å) 0.024
r.m.s.d bond angles (°) 2.3
Average B factor (Å
2) 40.1
PDB code 2I5C
aData for the highest resolution shell are shown in parentheses.
Figure 3 CPH/IP5 structures. Cartoon representations of the crystal structures of CPH bound to IP5(4) and IP5(6).T h eC P H / I P 5(4) structure is
shown in yellow and the CPH/IP5(6) structure in pink. Electron density maps (2fo-fc) have been contoured at a sigma level of 2.0.
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ciation of PHAkt but did not report the analysis of the
other IP5 isomers. The results for CPH/IP5 binding sug-
gest it is possible that another IP5 isomer could be a
better inhibitor of PHAkt phosphoinositide binding.
We tested the ability of IP5 isomers to inhibit binding
of PHGrp1 and PHAkt to liposomes containing PtdIns(3,4)
P2.A ss h o w ni nF i g u r e5 ,p a n e lA ,P H Grp1 binding to
PtdIns(3,4)P2 was inhibited in a similar way by all IP5 iso-
mers (P value 0.1054). Therefore, in contrast to CPH,
PHGrp1 does not appear to specifically recognize different
IP5 isomers to any significant extent. Further analysis of
the inhibitory properties of these isomers towards Akt/
PtdIns(3,4)P2 binding did reveal significant differences in
specificity, see Figure 5, panel B (P value 0.0002). IP5(4)
was the most effective inhibitor followed by IP5(6) and IP5
(2). Weakest inhibition of PHAkt/PtdIns(3,4)P2 binding
was observed for IP5(3) followed by IP5(1) and IP5(5)
respectively. These differences suggest that like CPH,
PHAkt provides sufficient specificity in its binding pocket
to differentiate between very similar ligands.
This is a particularly interesting finding given that pre-
vious studies have reported that IP5(2) is able to prevent Akt
localization to membranes by competing with phosphoino-
sitides for binding to its PH domain. As a consequence, the
serine phosphorylation and kinase activity of Akt are inhib-
ited resulting in apoptosis in ovarian, lung and breast cancer
cells [14,19,20]. Not surprisingly, much interest exists in
developing inhibitors to Akt, some of which are based on
IP5(2) [21,22]. Our results suggest that IP5(4) is a more effec-
tive inhibitor and may therefore provide a better starting
compound for inhibitor design compared to IP5(2).
Structural determinants of IP5 specificity
Collectively these results demonstrate that some PH
domains possess enough specificity to differentiate
Figure 4 Specific interactions between CPH and IP5 ligands. Detailed stereo views of the protein/ligand interactions made between CPH and
IP5(4) and IP5(6). The CPH/IP5(4) structure is shown in yellow and the CPH/IP5(6) structure in pink. Selected interactions are shown by broken lines.
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for different classes of inositol phosphates among PH
domains is not a new idea, the ability to recognize very
subtle differences, such as those found in the IP5 family,
has not been well appreciated. In an attempt to under-
stand the structural basis for the high degree of specifi-
city observed we compared the structures of CPH,
PHGrp1 and PHAkt.
Examination of the inositol phosphate binding pockets
from CPH, PHGrp1 and PHAkt revealed two important
differences. PHGrp1 (no IP5 specificity) contains 7 basic
residues whereas CPH and PHAkt (good IP5 specificity)
contain 6 and 4 basic residues, respectively. This sug-
gests that the number of basic residues in the binding
pocket influences IP5 specificity. If so, a possible expla-
nation is that too many basic residues physically restrict
the possible orientations that IP5 isomers can adopt in
the binding pocket. Orientation plays an important role
in specificity as demonstrated for CPH. Here, IP5(4) and
IP5(6) adopted different orientations in the binding
pocket resulting in different binding affinities. It is rea-
sonable to expect that as a binding pocket contains
increasing numbers of basic residues the space available
for IP5 isomers to adopt different orientations will be
decreased. The resulting limited orientation(s) may per-
mit a high affinity interaction (due to the abundance of
basic residues) but the affinity will be similar for all iso-
mers. In further support of an “orientation-restricted”
binding pocket, PHGrp1 contains a 20-residue insertion
in the b6/b7l o o pt h a tf o r m sab hairpin structure. This
b hairpin, not found in CPH or PHAkt, folds back and
over top of the b1/b2 loop, essentially capping the bind-
ing pocket (Figure 6). This added structural feature
further restricts possible orientations that could other-
wise be adopted by IP5 isomers. In support of this, the
orientations of IP5(2) (PDB code: 1FHW) and that of Ins
(1,3,4,5)P4 (PDB code: 1FGY) which were both solved
bound to Grp1 [3,4], adopt identical orientations in the
binding pocket (colored pink and blue respectively in
Figure 6 Surface representation of the PHGrp1. (PDB code: 1FGY)
binding pocket shown in stereo. b6/b7 insertion is colored red. IP5(6) is
colored yellow, IP5(2) is colored pink and Ins(1,3,4,5)P4 is colored blue.
Table 2 CPH/Ligand interaction details
CPH/IP5(4) CPH/IP5(6)
Contact Contact
Residue Dist Surf H E V Residues Dist Surf H E V
K253 2.8 29.7 + + + K253 2.8 46.4 + + -
G255 3.0 37.9 + - + G255 3.2 28.2 - - +
H256 3.2 33.3 + - - H256 2.8 57.1 + - +
R257 2.7 79.2 + + - R257 3.0 62.2 + + -
R258 3.1 59.4 + + - R258 2.8 58.6 + + -
R259 3.6 2.9 + + - R259
N260 4.5 9.7 + - - N260
K262 3.9 39.3 + + + K262 4.9 12.8 + + -
R264 2.7 49.7 + + - R264 2.8 47.8 + + -
Y277 2.3 52.3 + - - Y277 2.6 41.9 + - +
L287 3.8 36.4 + - - L287 3.7 24.8 + - -
Y325 5.0 2.8 + - - Y325 3.8 7.4 + - +
Total 431.6 Total 387.2
Distances (Dist) are given in angstroms (Å) and represent the distance to the
closest protein atom. Surface (Surf) is the contact surface area between the
ligand and protein atoms (Å
2). H - hydrogen bond, E - electrostatic interaction
and, V - van der Waals. “+” and “-” indicate observed and not observed
interactions respectively.
Figure 5 Inhibition of PHGrp1 and PHAkt binding. Inhibition of
PHGrp1 and PHAkt (10 μM) binding to liposomes containing PtdIns
(3,4)P2 by myo-inositol pentakisphosphates (100 μM). Percent
inhibition is plotted on the y-axis for the different IP5 isomers.
Percent inhibition values are shown above the bars. Error bars
represent +/- standard error of mean (SEM).
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imposed by these structural features we have aligned the
CPH/IP5(6) structure with Grp1. The orientation adopted
by IP5(6) is forbidden in the binding pocket of Grp1 due
to steric clashes with the b6/b7 insertion. It is also pos-
sible that since basic residues have long and flexible side
chains, PH domains with a greater number of basic resi-
dues are more adaptable to different ligands and can
therefore accommodate different inositol phosphate
molecules with similar affinities.
Conclusion
Work presented here substantiates the growing body of
evidence that IP5’s regulate PH domain/phosphoinosi-
tide interactions [14,17,19,20]. Specifically, these results
demonstrate that the six IP5 isomers differ in their inhi-
bitory properties towards PH domains. This allows for
the potential to fine tune PH domain/phosphoinositide
signaling pathways. Our work has direct implications
f o rA k ts i g n a l i n ga sp r e v i o u ss t u d i e sh a v es h o w nt h a t
IP5(2) can inhibit membrane binding and subsequent
activation of Akt [14,19,20]. In light of our findings, it
would be prudent to include all IP5 isomers in future
binding studies involving PH domains and IP5.T h e
potential for a high degree of specificity demonstrated
here could in theory be extended to other families of
inositol phosphates. Given that there are 63 possible
inositol phosphates this provides nature with an expan-
sive toolbox for regulating phosphoinositide based
signaling pathways.
In addition to their potential role as signaling mole-
cules, IP5’s could also be used as inhibitors to probe bio-
logical pathways. A potential issue in administering
exogenous IP5’s is their low cell permeability. Fortu-
nately, much progress has been made towards overcom-
ing this problem. By masking phosphate and hydroxyl
groups as esters, the hydrophobicity and membrane per-
meability is significantly increased [23]. Once inside the
cell the ester groups are removed by host esterases
yielding the original IP5 molecule (available from
SiChem). A similar approach can now be applied to
phosphoinositides yielding new cell permeant tools for
studying these signaling pathways [24,25].
Methods
Protein expression and purification
CPH was expressed and purified as described pre-
viously [17]. PHGrp1 (residues 260-390) was cloned into
the pDEST17 expression vector (Invitrogen). Escheri-
chia coli B L 2 1 ( D E 3 )c e l l sw e r eg r o w ni ns t a n d a r dL B
medium supplemented with 10 mg ml
-1 ampicillin at
37.0°C with shaking (225 rev min
-1) until the light
absorbance at 600 nm reached 0.5. The temperature
was then lowered to 20.0°C and protein expression was
induced using 1.0 mM IPTG. Following a 5 hour
induction period cells were harvested by centrifugation
at 3 315 × G and 4.0°C for 15 minutes. The resulting
cell pellets were flash frozen in liquid nitrogen and
stored at -80.0°C. Prior to cell lysis using a French
press, pellets were resuspended in 35 ml with NiA buf-
fer (20 mM Tris-HCl pH 7.5, 1 M KCl, 5 mM imida-
zole and 10% glycerol). Cell lysates were centrifuged at
48 384 × G and 4.0°C for 45 minutes. The resulting
supernatant was applied to a HiTrap Nickel affinity
column (GE Healthcare). PHGrp1 was eluted from the
column using NiA buffer supplemented with 500 mM
imidazole following sequential washes with NiA buffer
containing 20 and 45 mM imidazole. The protein sam-
ple was buffer exchanged into 20 mM Tris-HCl pH 7.5
and 300 mM KCl using a HiPrep 26/10 desalting col-
umn (GE Healthcare). The hexahistidine tag was
removed by cleavage with TEV protease. This resulted
in four residues (Gly, Ser, Phe and Thr) being retained
o nt h eN - t e r m i n a ls i d eo ft h ef i r s tr e s i d u eo fP H Grp1.
The salt concentration was diluted to 100 mM KCl
using SA buffer (20 mM Tris-HCl pH 7.5) and the
sample applied to a HiTrap SP Sepharose ion exchange
column (GE Healthcare). PHGrp1 was eluted using an
increasing salt gradient through the application of
increasing amounts of SB buffer (20 mM Tris-HCl pH
7.5 and 1 M KCl). The resulting PHGrp1 sample was
buffer exchanged into 20 mM Tris-HCl pH 7.5,
100 mM KCl, 2 mM TCEP and 10% glycerol and sub-
sequently concentrated using a centrifugal filter.
PHGrp1 purified in this manner is greater the 95% pure
as judged by SDS-PAGE. PHAkt (residues 1-123) was
cloned into the pDEST-HisMBP expression vector
(Addgene plasmid #11085). The fusion protein was
expressed and purified in the same manner as PHGrp1.
Crystallization and data collection of the CPH/IP5(6)
complex
CPH (2.5 mg ml
-1) was crystallized in the presence of 1
mM IP5(6) (Sichem GmbH, Germany) using the hanging
drop vapour diffusion method under the following con-
ditions. Inositol phosphates are purified by HPLC to
greater the 98% purity. A 3 μl drop containing 2 μlo f
CPH (2.5 mg ml
-1) and 1 mM IP5(6) in the crystallization
buffer described above and 1 μlo f0 . 1MB i s - T r i sp H6 . 5
and 28% polyethylene glycol 2000 monomethyl ether
was suspended over 500 μlo f0 . 4 5Ma m m o n i u ms u l f a t e
and incubated at 21.0°C. Crystals possessing bypyrami-
dal morphology grew to their maximum size after 72
hours. A single high-resolution data set (1.7 Å) was col-
lected at a wavelength of 0.9797 Å at beamline X26-C of
the Brookhaven National Laboratory using a ADSC
Quantum-4 CCD area detector. The data were pro-
cessed using the HKL2000 program suite [26].
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The crystal structure of CPH in complex with IP5(6) was
solved by molecular replacement using the program
MOLREP [27]. The search model used in molecular
replacement was the crystal structure of apo-CPH (PDB
code 1ZM0). Iterative cycles of model building and
refinement were carried out using the programs Win-
Coot [28] and Refmac5 [29] respectively. Ligand-Protein
Contacts (LPC) were derived with LPC software [30].
All figures describing protein structures presented in
this report were generated using PyMol [31].
PH domain/IP5 inhibition assays
All measurements were made using a ProteOn XPR36
surface plasmon resonance instrument equipped with an
N L Cs e n s o rc h i p( B i o r a d ) .T h es e n s o rc h i ps u r f a c ew a s
pre-treated with three sequential injections (30 μlm i n
-1
for 1 min) of SPR buffer (20 mM Tris-HCl pH 7.5,
100 mM KCl and 2% glycerol), 5 mM NaOH and SPR
buffer. Liposomes containing 5 mole % PtdIns(3,4)P2
and 1 mole % biotinylated phosphatidylethanolamine
(Echelon Biosciences) were diluted to 10 μMi nS P R
buffer and applied in sequential injections (25 μlm i n
-1
for 3 mins) until approximately 1000 response units
(RU) had been applied to the sensor chip surface. The
liposome surface was then washed with a single injec-
tion (30 μlm i n
-1 for 1 min) of 1 mM NaOH. PH
domains (final concentration of CPH was 50 μMa n d
was 10 μMf o rP H Grp1 and PHAkt), diluted in SPR buf-
fer, were injected (30 μlm i n
-1 for 2 mins) to determine
the level of binding in the absence of inhibitor. For inhi-
bition experiments, PH domains were incubated with
specific IP5 isomers prior to injection across the lipo-
some surface. PH domain/IP5 samples were injected at
30 μl/min for 2 minutes. Surfaces were regenerated with
2 sequential injections of 5 mM NaOH at 50 μlm i n
-1
for 30 seconds. Sample signals were corrected by sub-
tracting the signal obtained by injecting sample across
liposome free surfaces. The PH domain/IP5 signals were
compared to PH domain only signals to determine the
relative inhibitory properties of each IP5 isomer. This
comparison was made after binding of PH domain and
PH domain/IP5 samples reached steady state equili-
brium. To calculate percent inhibition, the signal from a
specific time point, when binding had reached equili-
brium, was taken for all samples. The signal for PH
domain alone samples was used as the standard for
complete binding (100%). Signal obtained for PH
domain/IP5 samples were compared to this standard to
determine the percent inhibition. All measurements
were made in triplicate. All experiments were conducted
at 21.0°C. The statistical significance of differences in
the inhibitory properties was assessed by an analysis of
variance using the GraphPad InStat software package
(GraphPad Software).
Additional material
Additional File 1: Interactions between CPH and IP5 ligands. This file
provides a table listing all of the interactions and distances observed
between CPH and IP5(4) and IP5(6) isomers.
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